Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 3/20 | 0.57 |
| ▸ | RARA | P10276 | 1/20 | 0.57 |
| ▸ | RARG | P13631 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20476364 | 0.99 | RARB (0.59) | RARBRARARARGPPARAPPARG | |
| SCHEMBL7219535 | 0.89 | NPC1 (0.44) | RARBRARARARGPPARAPPARG | |
| SCHEMBL20772047 | 0.88 | CYP4A11 (0.59) | RARBRARARARGPPARAPPARG | |
| SCHEMBL20772393 | 0.87 | CYP4A11 (0.43) | RARBRARARARGPPARAPPARG | |
| SCHEMBL15173816 | 0.87 | KAT8 (0.54) | RARBRARARARGPPARAPPARG | |
| SCHEMBL20772389 | 0.87 | CYP4A11 (0.57) | RARBRARARARGPPARAPPARG | |
| SCHEMBL20772253 | 0.87 | CYP4A11 (0.58) | RARBRARARARGPPARAPPARG | |
| SCHEMBL28773091 | 0.86 | PPARA (0.58) | RARBRARARARGPPARAPPARG | |
| SCHEMBL20772052 | 0.86 | RARB (0.45) | RARBRARARARGPPARAPPARG | |
| SCHEMBL20772235 | 0.85 | CYP4A11 (0.42) | RARBRARARARGPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | RARB 877/4885RARA 864/4885RARG 823/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | RARB 877/4885RARA 864/4885RARG 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.